Hematologija
Clinical Outcomes
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (odpre novo okno)
Vir: Lancet Haematol 2018;5(3):e117-e126.
Indeksirano: PubMed 29396092
DOI: 10.1016/S2352-3026(18)30016-4
https://www.ncbi.nlm.nih.gov/pubmed/29396092 (odpre novo okno)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (odpre novo okno)
Vir: Cancer 2013;119(1):107-14.
Indeksirano: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (odpre novo okno)